newsfilter
← Latest News
PR Newswire·

RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022

ROCKVILLE, Md., Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. FDA has accepted i